Anavex Life Sciences Corp (AVXL) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Anavex Life Sciences Corp $1.02, price $2.34, upside -56.4%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Anavex Life Sciences Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $2.34 – $28.86 · fair‑value band $0.6800 – $1.28 · the $2.34 price screens above the $1.02 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Anavex Life Sciences in your weekly email
Every Wednesday you see whether Anavex Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer .
Show more
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Stock analysis
Anavex Life Sciences Corp (AVXL) currently trades at $2.34, while our model-based Fair Value estimate is $1.02, implying the stock looks roughly 129.4% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $0.6800 (bear) to $1.28 (bull), the price of $2.34 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Anavex Life Sciences Corp reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$46.4M in FY2025.
Key figures
Market cap $241M · EPS (TTM) $−0.1400 · Return on equity −12.8% · Return on assets (EBIT) −35.7% · Free cash flow −$39.0M · Net cash $103M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).
What moves the price
The share trades about 77% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −56%, AVXL screens richer than that median.
Fair Value models
Bear $0.6800Fair Value $1.02Bull $1.28
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Compare Anavex Life Sciences Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Above median
Fair Value upside−56% · Below median
Profitability
Return on assets−10% · Above median
Operating margin (TTM)0% · Above median
Growth and dividend
Revenue growth0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.54× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Anavex Life Sciences Corp Fair Value". https://www.fairvalue-calculator.com/stock/AVXL
Frequently asked questions
Is Anavex Life Sciences Corp (AVXL) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $1.02 versus a price of $2.34, about −56% upside (overvalued).
What is the fair value of AVXL?
Our model-based fair value for Anavex Life Sciences Corp is $1.02 (as of Sep 23, 2026), built from audited fundamentals. The current price: $2.34.
What is the quality score of AVXL?
Anavex Life Sciences Corp has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anavex Life Sciences Corp (AVXL)?
Our model-based price target is the fair value of $1.02 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.6800, optimistic scenario $1.28. It is a calculation from audited fundamentals, not an analyst target.
What is the Anavex Life Sciences Corp stock forecast for 2026?
Our models put fair value at $1.02, about −56% upside versus a price of $2.34 (overvalued). Cautious scenario $0.6800, optimistic scenario $1.28. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Anavex Life Sciences Corp (AVXL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anavex Life Sciences Corp it is $1.02 per share (as of Sep 23, 2026), against a price of $2.34. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Anavex Life Sciences Corp stock overvalued or undervalued in 2026?
As of Sep 23, 2026, AVXL trades above its calculated fair value: price $2.34, fair value $1.02, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AVXL?
No. The price is what the market pays today ($2.34); the fair value is what the company's own numbers justify ($1.02). For Anavex Life Sciences Corp the two are $1.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is Anavex Life Sciences Corp worth?
The market values Anavex Life Sciences Corp at about $241M (market capitalisation, as of Sep 23, 2026). Per share that is $2.34; our models calculate a fair value of $1.02 per share.
What do the bullish and bearish scenarios say about AVXL?
Our models span a range for Anavex Life Sciences Corp: cautious scenario $0.6800, base $1.02, optimistic $1.28 per share (as of Sep 23, 2026, price $2.34). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Anavex Life Sciences Corp (AVXL)?
Balance-sheet figures for Anavex Life Sciences Corp (as of Sep 23, 2026): return on equity −12.8%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is AVXL from its 52-week high?
Anavex Life Sciences Corp trades at $2.34, about 77% below its 52-week high of $9.96 and at the low of $2.34 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $1.02 is for.
Which stocks are comparable to Anavex Life Sciences Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anavex Life Sciences Corp stock attractive at the current price?
The data as of Sep 23, 2026: price $2.34, calculated fair value $1.02 (−56%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AVXL calculated?
We run Anavex Life Sciences Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.02, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Anavex Life Sciences Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anavex Life Sciences Corp (AVXL)?
The closing price on Sep 24, 2026 was $2.34. Our model-based fair value is $1.02, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anavex Life Sciences Corp right now?
The price sits above even our optimistic bull case ($1.28). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.6800 to $1.28) leaves room in how you read the outcome.
Key figures of Anavex Life Sciences Corp
How large is the market capitalisation of Anavex Life Sciences Corp (AVXL)?
The market capitalisation of Anavex Life Sciences Corp is $241M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Anavex Life Sciences Corp (AVXL)?
Earnings per share at Anavex Life Sciences Corp are $−0.1400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Anavex Life Sciences Corp (AVXL)?
The return on equity (ROE) of Anavex Life Sciences Corp is −12.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anavex Life Sciences Corp (AVXL)?
On an EBIT basis the return on assets of Anavex Life Sciences Corp is −35.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Anavex Life Sciences Corp (AVXL) generate?
The free cash flow of Anavex Life Sciences Corp is −$39.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Anavex Life Sciences Corp (AVXL) hold?
Anavex Life Sciences Corp holds more cash than debt, $103M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Anavex Life Sciences Corp in the live analysis
One click puts Anavex Life Sciences Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026